Technologies for the development of West Nile virus vaccines

被引:0
作者
Ulbert, Sebastian [1 ]
Magnusson, Sofia E. [2 ]
机构
[1] Fraunhofer Inst Cell Therapy & Immunol, Dept Immunol, D-04103 Leipzig, Germany
[2] Novavax AB, S-75318 Uppsala, Sweden
关键词
animal models; emerging virus; protective immune responses; vaccine development; West Nile Virus; NONSTRUCTURAL PROTEIN NS1; FC-GAMMA-RECEPTOR; DNA VACCINE; IMMUNE-RESPONSES; UNITED-STATES; DOMAIN-III; LINEAGE; NEUTRALIZING ANTIBODIES; JAPANESE ENCEPHALITIS; CHIMERIC VACCINE;
D O I
10.2217/FMB.14.67
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
West Nile virus (WNV), an emerging mosquito-borne and zoonotic flavivirus, continues to spread worldwide and represents a major problem for human and veterinary medicine. In recent years, severe outbreaks were observed in the USA and Europe with neighboring countries, and the virus is considered to be endemic in an increasing number of areas. Although most infections remain asymptomatic, WNV can cause severe, even fatal, neurological disease, which affects mostly the elderly and immunocompromised individuals. Several vaccines have been licensed in the veterinary sector, but no human vaccine is available today. This review summarizes recent strategies that are being followed to develop WNV vaccines with emphasis on technologies suitable for the use in humans.
引用
收藏
页码:1221 / 1232
页数:12
相关论文
共 50 条
  • [31] A DNA vaccine encoding the E protein of West Nile Virus is protective and can be boosted by recombinant domain DIII
    Schneeweiss, Anne
    Chabierski, Stefan
    Salomo, Mathias
    Delaroque, Nicolas
    Al-Robaiy, Samiya
    Grunwald, Thomas
    Buerki, Kurt
    Liebert, Uwe G.
    Ulbert, Sebastian
    VACCINE, 2011, 29 (37) : 6352 - 6357
  • [32] West Nile Virus in the New World: Trends in the Spread and Proliferation of West Nile Virus in the Western Hemisphere
    Artsob, H.
    Gubler, D. J.
    Enria, D. A.
    Morales, M. A.
    Pupo, M.
    Bunning, M. L.
    Dudley, J. P.
    ZOONOSES AND PUBLIC HEALTH, 2009, 56 (6-7) : 357 - 369
  • [33] Pre-clinical development of a hydrogen peroxide-inactivated West Nile virus vaccine
    Poore, Elizabeth A.
    Slifka, Dawn K.
    Raue, Hans-Peter
    Thomas, Archana
    Hammarlund, Erika
    Quintel, Benjamin K.
    Torrey, Lindsay L.
    Slifka, Ariel M.
    Richner, Justin M.
    Dubois, Melissa E.
    Johnson, Lawrence P.
    Diamond, Michael S.
    Slifka, Mark K.
    Amanna, Ian J.
    VACCINE, 2017, 35 (02) : 283 - 292
  • [34] West Nile Virus Emergence in Germany 2019: Looking for Hidden Human West Nile Virus Infections
    Lachmann, Raskit
    Domingo, Cristina
    Frank, Christina
    Ochs, Andreas
    Pauly, Andreas Karl
    Weber-Schehl, Marijke
    Schmidt, Michael
    Tonn, Torsten
    Mueller, Thomas H.
    Barzon, Luisa
    Sinigaglia, Alessandro
    Esquevin, Sarah
    Preussel, Karina
    Offergeld, Ruth
    VECTOR-BORNE AND ZOONOTIC DISEASES, 2024, 24 (06) : 396 - 401
  • [35] Prospects for development of a vaccine against the West Nile virus
    Monath, TP
    WEST NILE VIRUS: DETECTION, SURVEILLANCE, AND CONTROL, 2001, 951 : 1 - 12
  • [36] Development time of IgG antibodies to West Nile virus
    Papa, Anna
    Danis, Kostas
    Tsergouli, Katerina
    Tsioka, Katerina
    Gavana, Elpida
    ARCHIVES OF VIROLOGY, 2011, 156 (09) : 1661 - 1663
  • [37] West Nile Virus
    Rossi, Shannan L.
    Ross, Ted M.
    Evans, Jared D.
    CLINICS IN LABORATORY MEDICINE, 2010, 30 (01) : 47 - 65
  • [38] Development time of IgG antibodies to West Nile virus
    Anna Papa
    Kostas Danis
    Katerina Tsergouli
    Katerina Tsioka
    Elpida Gavana
    Archives of Virology, 2011, 156 : 1661 - 1663
  • [39] West Nile virus
    Phalen, DN
    Dahlhausen, B
    SEMINARS IN AVIAN AND EXOTIC PET MEDICINE, 2004, 13 (02): : 67 - 78
  • [40] Progress on the development of therapeutics against West Nile virus
    Diamond, Michael S.
    ANTIVIRAL RESEARCH, 2009, 83 (03) : 214 - 227